The SARS-CoV-2 test, which runs on Cepheid's GeneXpert systems, is to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as nasal swabs.
With nearly 7 million COVID-19 cases, the country is expanding near-patient strategies historically deployed for tuberculosis testing for SARS-CoV-2 testing.
A SNP in the pan-SARS E gene has not affected patient results, but has raised concerns about the overall unavailability of commercial primer and probe information.
For the three months ended July 3, the Washington DC-based conglomerate recorded $5.30 billion in total sales compared to $4.44 billion in the year-ago period.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
